Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Neuland Laboratories Limited's net profit margin of 17.4% in FY2025 reflects good profitability, with operating margin at 18.6% and gross margin at 60.8%.
In FY 2025, Neuland Laboratories Limited posted a gross margin of 60.8%, an operating margin of 18.6%, a net margin of 17.4%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Neuland Laboratories Limited's revenue declined 4.7% to 14.97B in FY2025, with net profit also falling 13.3% to 2.60B.
In FY 2025, Neuland Laboratories Limited's revenue declined by 4.7% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Neuland Laboratories Limited's ROE of 17.1% in FY2025 indicates good shareholder returns.
In FY 2025, Neuland Laboratories Limited reported an ROE of 17.1%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Neuland Laboratories Limited's FCF/NI ratio of 0.43x in FY2025 indicates FCF trailing profits — heavy capex or working capital needs may be a factor.
In FY 2025, Neuland Laboratories Limited's free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Neuland Laboratories Limited's OCF/NI ratio of 1.22x in FY2025 indicates sound cash management with earnings well-backed by cash.
In FY 2025, Neuland Laboratories Limited's operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Neuland Laboratories Limited's current ratio of 2.45x in FY2025 indicates healthy short-term liquidity.
In FY 2025, Neuland Laboratories Limited reported a current ratio of 2.45. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Neuland Laboratories Limited's interest coverage ratio of 33.5x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Neuland Laboratories Limited reported an interest coverage ratio of 33.5x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Neuland Laboratories Limited's debt-to-equity ratio of 0.10x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Neuland Laboratories Limited reported a debt-to-equity ratio of 0.10. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Neuland Laboratories Limited's debt increased 64.7% YoY in FY2025 — rising leverage demands close monitoring.
In FY 2025, Neuland Laboratories Limited's total debt increased by 64.7% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Neuland Laboratories Limited's diluted shares remained virtually unchanged in FY2025.
Over 2 years (FY2024–FY2025), diluted shares remained essentially unchanged at 12.83M.
In FY 2025, Neuland Laboratories Limited's diluted shares increased by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025